RY 142.67 0.2741% TD 73.88 -0.8721% SHOP 90.5 -0.9088% CNR 166.11 0.2414% ENB 47.82 -0.0209% CP 108.03 0.7273% BMO 115.21 0.2088% TRI 229.53 0.0131% CNQ 46.6 0.7568% BN 56.605 0.3991% ATD 76.65 -0.1173% CSU 3771.1299 -0.0005% BNS 63.59 -0.0943% CM 65.25 0.1535% SU 50.11 0.2802% TRP 52.57 0.2288% NGT 56.35 0.1422% WCN 238.17 0.4428% MFC 35.05 0.2001% BCE 44.76 -0.1339%

Arch Biopartners Inc

Healthcare CA ARCH

1.68CAD
0.02(1.20%)

Last update at 2024-06-18T13:47:00Z

Day Range

1.681.70
LowHigh

52 Week Range

0.972.82
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Type yearly yearly yearly yearly yearly
Date 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Income before tax -1.38936M -1.16971M -4.62866M -2.35761M -3.19822M
Minority interest - - - - -
Net income -1.38936M -1.16971M -4.62866M -2.35761M -3.19822M
Selling general administrative 0.77M 1.00M 2.57M 0.77M 1.73M
Selling and marketing expenses - - - - -
Gross profit - - - -1.67013M -1.50229M
Reconciled depreciation - - - - -
Ebit -0.99710M -0.81938M -4.37867M -1.91399M -2.93646M
Ebitda -1.08003M -0.89640M -4.45270M -2.24732M -3.13417M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income -1.08003M -0.89154M -4.45812M -2.25174M -3.16810M
Other operating expenses - - - - -
Interest expense 0.31M 0.27M 0.18M 0.11M 0.06M
Tax provision - - - - -
Interest income - - - - -
Net interest income -0.30933M -0.27331M -0.17596M -0.11029M -0.06405M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - 0.00000M
Total revenue 0.00000M 3.89M 0.07M 0.09M 0.00000M
Total operating expenses 1.08M 4.78M 4.53M 2.35M 3.17M
Cost of revenue - - - 1.76M 1.50M
Total other income expense net - -0.00486M 0.00543M 0.00442M 0.03M
Discontinued operations - - - - -
Net income from continuing ops -1.38936M -1.16971M -4.62866M -2.35761M -3.19822M
Net income applicable to common shares -1.40786M -1.16971M -4.62866M -2.09264M -3.01582M
Preferred stock and other adjustments - - - - -
Breakdown 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Type yearly yearly yearly yearly yearly
Date 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Total assets 0.62M 2.67M 0.74M 0.57M 0.67M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - - - - 0.18M
Total liab 5.09M 6.55M 4.61M 3.47M 1.72M
Total stockholder equity -4.47059M -3.88241M -3.86810M -2.90171M -1.04578M
Deferred long term liab - - - - -
Other current liab - - - - -
Common stock 15.55M 14.76M 13.71M 12.03M 11.81M
Capital stock 15.55M 14.76M 13.71M 12.03M 11.81M
Retained earnings -24.72422M -23.31636M -22.14665M -17.51800M -15.42535M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 0.51M 0.45M 0.65M 0.40M 0.54M
Cash and equivalents - - - - -
Total current liabilities 2.78M 3.19M 1.22M 0.58M 0.28M
Current deferred revenue - - - - -
Net debt 3.91M 4.72M 2.74M 2.48M 0.94M
Short term debt - - - - -
Short long term debt 2.10M 1.80M - - -
Short long term debt total - - - - -
Other stockholder equity - - - 0.01M -
Property plant equipment - - - - -
Total current assets 0.62M 2.67M 0.74M 0.83M 0.86M
Long term investments - - - - -
Net tangible assets -4.47059M -3.88241M -3.86810M -2.63674M -0.86338M
Short term investments - - - - -
Net receivables 0.09M 2.20M 0.06M 0.14M 0.11M
Long term debt 2.31M 3.36M 3.39M 2.89M 1.48M
Inventory - - - - -
Accounts payable 0.49M 0.96M 0.95M 0.47M 0.23M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - 0.00000M 0.00000M
Deferred long term asset charges - - - - -
Non current assets total 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Type yearly yearly yearly yearly yearly
Date 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Investments - - - - -
Change to liabilities 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total cashflows from investing activities - - - - -
Net borrowings -0.79130M 1.73M 0.49M 1.42M 1.07M
Total cash from financing activities -0.42137M 2.78M 2.16M 1.66M 2.65M
Change to operating activities - - - - -
Net income -1.40786M -1.16971M -4.62866M -2.09264M -3.01582M
Change in cash 0.06M -0.20544M 0.25M -0.14396M 0.50M
Begin period cash flow 0.45M 0.65M 0.40M 0.54M 0.04M
End period cash flow 0.51M 0.45M 0.65M 0.40M 0.54M
Total cash from operating activities 0.48M -2.98074M -1.90478M -1.80459M -2.15205M
Issuance of capital stock 0.37M 1.05M 1.67M 0.22M 1.58M
Depreciation - - - - -
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities - - - -0.00280M -0.01461M
Change to netincome 1.89M -1.81103M 2.72M 0.29M 1.05M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital - - - - -
Stock based compensation - - - - -
Other non cash items - - - - -
Free cash flow 0.48M -2.98074M -1.90478M -1.80459M -2.15205M

Fundamentals

  • Previous Close 1.66
  • Market Cap94.13M
  • Volume1300
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM2.49M
  • Revenue Per Share TTM0.04
  • Gross Profit TTM -0.50288M
  • Diluted EPS TTM-0.06

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ARCH
Arch Biopartners Inc
0.02 1.20% 1.68 - - 37.82 - 53.05 -28.1027
NGEN
NervGen Pharma Corp
-0.02 0.86% 2.30 - - - 29.48 -6.9477
MIR
MedMira Inc
-0.005 5.88% 0.08 - - 170.46 - 189.94 -48.7372
TTI
Thiogenesis Therapeutics Corp.
- -% 0.70 - - - 11.86 -163.0787
SBM
Sirona Biochem Corp
0.005 9.09% 0.06 - - 343.74 41.64 359.74 -13.882

Reports Covered

Stock Research & News

Profile

Arch Biopartners Inc., a biotechnology company, engages in the development of technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat dipeptidase-1 mediated organ inflammation in the lungs, liver, and kidneys, which results in organ damage or failure, including in the case of sepsis and COVID-19. The company also develops AB569, an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds. In addition, it develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. Arch Biopartners Inc. is based in Toronto, Canada.

Arch Biopartners Inc

27 Street Clair Avenue East, Toronto, ON, Canada, M4T 2M5

Key Executives

Name Title Year Born
Mr. Richard Gabriel Muruve Co-Founder, CEO, Pres & Director 1971
Dr. Daniel Abraham Muruve Co-Founder, Chief Science Officer & Member of Scientific Advisory Board NA
Mr. Andrew Bishop CFA Acting CFO & Director 1966
Dr. Justin MacDonald Co-Founder & Principal Scientist NA
Dr. Paul Beck Co-Founder & Principal Scientist NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).